Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

BACKGROUND: Telotristat ethyl is approved to treat carcinoid syndrome diarrhea in combination with somatostatin analogs. In TELESTAR and TELECAST phase III studies, patients with carcinoid syndrome received telotristat ethyl 250 or 500 mg 3 times per day (tid) or placebo tid in addition to somatosta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Cancer
Main Authors: Dillon, Joseph S., Kulke, Matthew H., Hörsch, Dieter, Anthony, Lowell B., Warner, Richard R. P., Bergsland, Emily, Welin, Staffan, O’Dorisio, Thomas M., Kunz, Pamela L., McKee, Chad, Lapuerta, Pablo, Banks, Phillip, Pavel, Marianne
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7714089/
https://ncbi.nlm.nih.gov/pubmed/32146619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12029-020-00375-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados